We are investigating a new treatment combining Trastuzumab Deruxtecan with immunotherapy and chemotherapy for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer. The study aims to evaluate the safety and tolerability of this approach.
Health conditions and diseases that the clinical trial is designed to study and treat.
HER2 positive non-small cell lung cancer (NSCLC) is a type of lung cancer where the cancer cells have high levels of the HER2 protein, which can promote cancer growth. This condition often requires targeted therapies that specifically address the HER2 protein.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
